TY - JOUR
T1 - Ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria
T2 - understanding nebulization of aminoglycosides and colistin
AU - The European Investigators Network for Nebulized Antibiotics in Ventilator-associated Pneumonia
AU - Rouby, J. J.
AU - Sole-Lleonart, C.
AU - Rello, J.
AU - Monsel, Antoine
AU - Constantin, Jean Michel
AU - Bouglé, Adrien
AU - Blot, Stijn
AU - Poulakou, Garyphalia
AU - Pontikis, Konstantinos
AU - Kyriakoudi, Anna
AU - Koutsoukou, Antonia
AU - Dimopoulos, George
AU - Routsi, Christina
AU - Arvaniti, Kostoula
AU - Pereira, Jose Manuel
AU - Felton, Timothy
AU - Dhanani, Jayesh
AU - Roberts, Jason
AU - Bassetti, Matteo
AU - Welte, Tobias
AU - Dugernier, Jonathan
AU - Laterre, Pierre François
AU - Ehrmann, Stephan
AU - Boisson, Matthieu
AU - Mimoz, Olivier
AU - Leone, Marc
AU - Palmer, Lucy B.
AU - Pugin, Jérôme
AU - Qu, Jie ming
AU - Zhu, Ying gang
AU - Liao, Xuelian
PY - 2020
Y1 - 2020
N2 - The use of nebulized antibiotics for treating ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR) Gram-negative bacteria (GNB) increases worldwide. There is a paradox, however, between the large body of experimental evidence supporting the administration of nebulized rather than intravenous aminoglycosides and colistin to treat inoculation pneumonia caused by GNB [1, 2], and the paucity of clinical studies confirming such a benefit in VAP. Based on the recommendations of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) [3, 4], the present article examines this apparent contradiction and suggests some directions for further research and clinical practice.
AB - The use of nebulized antibiotics for treating ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR) Gram-negative bacteria (GNB) increases worldwide. There is a paradox, however, between the large body of experimental evidence supporting the administration of nebulized rather than intravenous aminoglycosides and colistin to treat inoculation pneumonia caused by GNB [1, 2], and the paucity of clinical studies confirming such a benefit in VAP. Based on the recommendations of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) [3, 4], the present article examines this apparent contradiction and suggests some directions for further research and clinical practice.
U2 - 10.1007/s00134-019-05890-w
DO - 10.1007/s00134-019-05890-w
M3 - Article
AN - SCOPUS:85077623687
SN - 0342-4642
JO - Intensive care medicine
JF - Intensive care medicine
ER -